CDX 模型

CDX 肿瘤模型服务,研究设计在前期就做到位。已建立及定制的细胞株异种移植模型在 AAALAC 认证设施中运行,生长特征分析、给药优化与终点分析均与研究所需支持的决策相匹配。

皮下
疾病模型数量模型
膀胱癌4RT112; HT-1376; RT112 84; UM-UC-3 
乳腺癌14MDA-MB-231(x);MDA-MB-468(x2); MDA-MB-436; DU4475; HCC70; MX-1(TNBC total 6);MCF-7(x); ZR-75-1;BT-474(x); T-47D(x); HCC1569; HCC1954; MCF-7-Her2(x); BT-474EEI
宫颈腺癌1Hela
结直肠癌12HCT-116; SW620; HT-29; SW480; DLD-1; COLO 205; NCI-H716; RKO; SW948; Colo320DM; LOVO; KM12-Luc
子宫内膜腺癌2AN3CA; MFE-296
表皮样癌2A431; CAL-27
上皮样肉瘤1VA-ES-BJ  
食管癌1T.T                   
纤维肉瘤1HT-1080
胃癌8HGC-27(x); MKN-45; AGS; NCI-N87; SNU-16; OCUM-1; SNU-5; MKN-1
胶质母细胞瘤7U87MG; U87MG (nude Rat); U87MG-EGFR VIII, LN229; U251; AM-38; AM-38-Luc
下咽癌1FaDu
肾癌 6Caki-1; A-498; 786-O; G-401; ACHN; OS-RC-2
白血病22K562; HL-60; MV-4-11; MOLT-4; Kasumi-1; KU812; THP-1; TF-1; HEL 92.1.7; SKM-1; NOMO-1; ARH-77; Kopn-8; MOLM-13; KG-1; OCI-AML-2 (nude Rat); OCI-AML-3 (nude Rat); OCI-AML-2; OCI-AML-3; RS4;11; EOL-1; SKNO-1
肝癌 6Hep 3B2.1-7; SK-HEP-1; HuH-7; Hep3B-OS8-Hpdl1a2; HepG2; JHH-7
肺癌 65NCI-H446; NCI-H2171; NCI-H841; SHP-77; DMS 53; NCI-H69;NCI-H209; NCI-H524; NCI-H1048; NCI-H1930; DMS 79; NCI-H2081; NCI-H1092; NCI-H146; DMS 153; NCI-H2029; NCI-H1417; NCI-H510A; NCI-H526 (SCLC-total 19)NCI-H1568; NCI-H1155; NCI-H2122; NCI-H522; NCI-H1975; NCI-H838; NCI-H358; NCI-H1299; PC-9; NCI-H2228;NCI-H1770;NCI-H2030;NCI-H1993;NCI-H1703; NCI-H647; HCC15; NCI-H1693; NCI-H2106; COR-L105; A549; NCI-H460;NCI-H292 ; NCI-H2009; Calu-3; Calu-6; NCI-H441; NCI-H727; HCC827; NCI-H661; ChaGo-K-1; NCI-H1650; NCI-H596;NCI-H1395;A-427; EBC-1; GCT;NCI-H226; NCI-H1373; RERF-LC-AI; SW 1573; HCC4006, LXF-289; HARA; SK-MES-1; LK2; ABC-1 (NSCLC total 46)
淋巴瘤22NAMALWA; Daudi; Raji; Mino; DB; Toledo; SU-DHL-6; MC116;  OCI-Ly19; 
WSU-DLCL2; Z-138; REC-1; Granta-519; RPMI 6666; Pfeiffer(x); Maver-1; Farage; SUDHL-5(x); JeKo-1; DoHH2; JVM-2; BJAB
甲状腺髓样癌1TT
髓母细胞瘤1Daoy
黑色素瘤5A375; A2058; C32; IGR-1;WN266-4
间皮瘤4TO211H; NCI-H28; NCI-H226; ACC-MESO-1(x) 
骨髓瘤8RPMI 8226; MM.1S; NCI-H929; U266B1; OPM-2; LP-1; HuNS1; MM.1R
鼻咽癌1CNE
神经母细胞瘤 5BE(2)-C; SH-SY5Y; SK-N-DZ; CHP-212; KELLY
骨肉瘤3143B; SJSA-1; SK-ES-1         
卵巢癌 10OVCAR-3; A2780; A2780 (nude Rat); Caov-3; SKOV-3; OVIES; TOV21G; OVK18; COV434; TOV112D
胰腺癌10MIA PaCa-2; Capan-1; PANC-1; AsPC-1; CFPAC-1; BxPC-3; KP4; Panc.08.13; HPAF-II; Panc.03.27
前列腺癌5PC-3; LNCaP(x1,x2); DU145; 22RV1; MDA-PCA-2B(+M)
横纹肌肉瘤2G-401; SJRH30

原位
疾病模型数量模型
乳腺癌4MDA-MB-468; MDA-MB-231;xMDA-MB-468-luc; xMDA-MB-231-Luc
结直肠癌1HCT116-luc
胶质母细胞瘤4U87MG; U87 MG-EGFRvIII-Luc; U87MG-Luc; U251-Luc
人多发性骨髓瘤1RPMI8226
肝癌2Hep3B-Luc ; SK-Hep-1-luc
肺癌1NCI-H1299-luc
卵巢癌2OVCAR-3, SKOV-3-Luc
前列腺癌2PC-3-luc; x1LNCap-luc

全身-生存期
疾病模型数量模型
白血病10K562;KU812;MV-4-11;HEL 92.1.7; XHP-1;HL-60; MOLM-13, RS4;11; MV-4-11-Luc; OCI-AML3-Luc2
肝癌1HepG2-Luc 
淋巴瘤4NAMALWA; Daudi; Raji; Raji-luc
骨髓瘤2LP-1; KMS34
神经母细胞瘤1BE(2)-C 

转移性
疾病模型数量模型
乳腺癌2xBT-474-Luc (脑内接种, 颈动脉)
结肠癌1HCT-116-Luc(原位接种)
胶质母细胞瘤1U-87 MG-Luc (前列腺内接种)
肺癌6NCI-H1299-Luc (脑内接种); PC-9-luc (脑内接种); NCI-H358-Luc2 (脑内接种); NCI-H1975-Luc (脑内接种); NCI-H1975-Luc (颈动脉内接种); PC-9-Luc (颈动脉内接种)
黑色素瘤3A-375 (脑内接种); A375- luc (心内接种,脑内)
卵巢癌2SK-OV-3-Luc(原位接种);  SK-OV-3-Luc (腹水接种)
前列腺癌2PC-3-Luc (心内接种,原位接种)
开启探索之旅
阶段
药物类型
治疗领域